New AI Platform Significantly Reduces Drug Discovery Costs and Time

Researchers have developed AdaptiveFlow, an AI-informed open-source platform that can virtually screen billions of drug-like molecules. This platform achieves a 1,000-fold reduction in computational costs compared to existing methods, as published in Nature Biotechnology. By integrating an ultra-large virtual molecule library and an advanced computational framework, AdaptiveFlow can shorten drug discovery timelines from months to hours, potentially accelerating pharmaceutical development.